HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study.
Cancers (Basel)
; 14(20)2022 Oct 11.
Article
en En
| MEDLINE
| ID: mdl-36291765
Texto completo:
1
Base de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
Idioma:
En
Revista:
Cancers (Basel)
Año:
2022
Tipo del documento:
Article